Xilio Therapeutics Inc (XLO)
NASDAQ:XLO
Want to see XLO full AI Analyst Report?
Top Page
Xilio Therapeutics
(NASDAQ:XLO)
Select Model
Select Model
Rating:47Neutral
Price Target:
$8.00
▲(1255.93% Upside)
Action:Reiterated
Date:06/13/26
The score is held back primarily by weak financial performance: large operating losses and significant ongoing cash burn outweigh improving revenue growth and low leverage. Technicals are neutral-to-mildly improving in the short term but remain below the long-term trend, while valuation is pressured by negative earnings and no dividend support. Corporate events are mildly positive but not a major driver versus the funding and execution risks implied by current fundamentals.
Positive Factors
Revenue Growth & Gross Margin
Meaningful TTM revenue growth paired with a roughly 73% gross margin indicates improving top-line traction and efficient product economics for biologics. Over 2–6 months this supports program viability and suggests the platform can sustain strong unit economics as clinical assets mature toward commercialization.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow indicate continued heavy funding needs to advance trials. Over several months this creates structural reliance on external capital, increases dilution risk, and could force prioritization or delay of programs if fundraising conditions tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Gross Margin
Meaningful TTM revenue growth paired with a roughly 73% gross margin indicates improving top-line traction and efficient product economics for biologics. Over 2–6 months this supports program viability and suggests the platform can sustain strong unit economics as clinical assets mature toward commercialization.
Read all positive factors
Xilio Therapeutics (XLO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$57.80M
Dividend YieldN/A
Average Volume (3M)51.50K
Price to Earnings (P/E)―
Beta (1Y)0.30
Revenue Growth476.71%
EPS Growth70.23%
CountryUS
Employees64
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.50
Shares Outstanding6,575,139
10 Day Avg. Volume33,079
30 Day Avg. Volume51,498
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)21.23
Price to Sales (P/S)17.11
P/FCF Ratio-135.93
Enterprise Value/Market Cap-1.49
Enterprise Value/Revenue-1.61
Enterprise Value/Gross Profit-2.28
Enterprise Value/Ebitda2.88
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.39
Revenue Forecast (FY)$27.31M
Xilio Therapeutics Business Overview & Revenue Model
Company Description
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal an...
How the Company Makes Money
Xilio Therapeutics does not have recurring product revenue because it is a clinical-stage biotechnology company and, as of the latest publicly available information, has not commercialized any approved therapies. The company primarily funds operat...
Xilio Therapeutics Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.48M | 43.77M | 6.34M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 37.81M | 42.23M | 6.34M | 0.00 | 0.00 | -1.50M |
| EBITDA | -29.91M | -33.49M | -58.00M | -74.50M | -86.38M | -73.70M |
| Net Income | -31.30M | -35.04M | -58.24M | -76.40M | -88.22M | -75.80M |
Balance Sheet | ||||||
| Total Assets | 163.49M | 154.69M | 71.08M | 60.93M | 139.16M | 221.60M |
| Cash, Cash Equivalents and Short-Term Investments | 150.33M | 137.53M | 55.29M | 44.70M | 120.39M | 198.05M |
| Total Debt | 6.64M | 6.95M | 8.14M | 11.46M | 19.94M | 20.74M |
| Total Liabilities | 90.94M | 119.41M | 53.48M | 24.10M | 33.52M | 36.17M |
| Stockholders Equity | 72.55M | 35.27M | 17.60M | 36.83M | 105.65M | 185.43M |
Cash Flow | ||||||
| Free Cash Flow | -57.37M | -5.51M | -18.41M | -69.11M | -77.59M | -81.85M |
| Operating Cash Flow | -56.31M | -4.99M | -18.38M | -68.62M | -75.72M | -80.75M |
| Investing Cash Flow | -1.05M | -518.00K | -36.00K | -486.00K | -1.87M | -1.10M |
| Financing Cash Flow | 118.65M | 87.78M | 29.20M | -6.55M | -69.00K | 260.67M |
Xilio Therapeutics Technical Analysis
Positive
0.59
Price Trends
8.23
Positive
8.07
Positive
9.19
Negative
Market Momentum
0.08
Negative
61.95
Neutral
74.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XLO, the sentiment is Positive. The current price of 0.59 is below the 20-day moving average (MA) of 8.25, below the 50-day MA of 8.23, and below the 200-day MA of 9.19, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 61.95 is Neutral, neither overbought nor oversold. The STOCH value of 74.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XLO.
Xilio Therapeutics Risk Analysis
Xilio Therapeutics disclosed 86 risk factors in its most recent earnings report. Xilio Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Xilio Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $48.36M | -2.68 | -0.97% | ― | ― | 21.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $398.03M | -5.34 | -94.90% | ― | -71.26% | -300.04% | |
49 Neutral | $125.93M | -3.97 | -49.43% | ― | ― | ― | |
48 Neutral | $365.55M | -41.97 | -106.16% | ― | ― | 63.03% | |
47 Neutral | $57.80M | -45.91 | -117.24% | ― | 476.71% | 70.23% | |
42 Neutral | $81.68M | -12.90 | 102.92% | ― | ― | ― |
* Healthcare Sector Average
XLO
Xilio Therapeutics
8.79
-0.85
-8.81%
FBRX
Forte Biosciences
17.85
3.19
21.76%
XFOR
X4 Pharmaceuticals
4.22
1.55
58.05%
LTRN
Lantern Pharma
3.79
0.61
19.18%
CNTB
Connect Biopharma Holdings
2.00
0.97
94.17%
OKYO
OKYO Pharma Limited Sponsored ADR
1.59
-0.78
-32.91%
Xilio Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Xilio Therapeutics Adjusts Board Structure Following Shareholder Votes
Positive
Jun 12, 2026
At its annual meeting on June 10, 2026, Xilio Therapeutics rebalanced its classified board by accepting the contingent resignation of Daniel Curran, M.D., as a Class II director and immediately reappointing him as a Class III director, resulting i...
Executive/Board Changes
Xilio Therapeutics Announces Board Changes and Committee Leadership
Neutral
Apr 16, 2026
On April 15, 2026, Xilio Therapeutics appointed Cheryl R. Blanchard, Ph.D., as a Class III director with a term running through the 2027 annual meeting, while naming her chair of the Compensation Committee and a member of the Audit Committee. Her ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.